Key facts
- This page summarizes Foresite Capital Management V, LLC's Form 4 filing for Theseus Pharmaceuticals, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Jul 2023, 14:54.
Foresite Capital Management V, LLC - 17 Jul 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 17 Jul 2023
- Net transaction value
- +$2,079,000
- SEC form
- 4
- Accepted by SEC
- 19 Jul 2023, 14:54:37 UTC
- Prior SEC filing
- 06 Apr 2023
- Next SEC filing
- 27 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- FORESITE CAPITAL MANAGEMENT V, LLC, By: /s/ James B. Tananbaum, Managing Member
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Foresite Capital Management V, LLC filed Form 4 for Theseus Pharmaceuticals, Inc. on 19 Jul 2023.
Change
- Previous filing in this sequence was filed on 06 Apr 2023.
- Current net transaction value: +$2,079,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
THRX
transaction
Common Stock
Purchase
- Transaction value
- $1,554,646
- Shares
- +523,450
- Change %
- +15%
- Price
- $2.97
- Shares after
- 4,108,796
- Date
- 17 Jul 2023
- Ownership
- See Footnote
- Footnotes
- F1
THRX
transaction
Common Stock
Purchase
- Transaction value
- $524,354
- Shares
- +176,550
- Change %
- +15%
- Price
- $2.97
- Shares after
- 1,385,825
- Date
- 17 Jul 2023
- Ownership
- See Footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Footnote F2
The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.